Revive Therapeutics Expands into Phase III Clinical Trials

August 26, 2020

Revive Therapeutics Expands into Phase III Clinical Trials

Revive Therapeutics will expand their candidate, Bucillamine, in patients with mild-moderate COVID-19 in phase III trials taking place in the Asia-Pacific Countries (“APAC”) and Canada. Revive expects to open the Phase 3 clinical trial for patient enrollment and dosing in September 2020. Yourway has a depot in Mississauga, Ontario in Canada, as well as in Beijing, China, Tokyo, Japan, Singapore, and Adelaide, Australia.

Back to Index

Stay Connected

Want to stay informed about the latest news, updates, and opportunities at Yourway?

Join our newsletter mailing list to never miss an update!

Media

Upcoming Events

Clinical Trial Supply Europe

February 24-26, 2026
Hyatt Regency, Barcelona Tower

Schedule a Meeting

Global Clinical Supplies Group Asia Pacific Conference

March 10-12, 2026
Conrad Seoul Hotel, South Korea

Schedule a Meeting

Media

Articles

Why Integration Matters in Clinical Supply Chains

Open chat

Hello! How can I help you?